The U.S. Food and Drug Administration has accepted Ionis Pharmaceuticals Inc.'s (NASDAQ: IONS) new drug application for zilganersen, an experimental ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA